Metadherin contributes to epithelial-mesenchymal transition and paclitaxel resistance induced by acidic extracellular pH in nasopharyngeal carcinoma

CHANGYUN YU¹, YONG LIU² and ZHAOBING QIN¹

¹Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000; ²Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China

Received July 24, 2016; Accepted November 16, 2017

DOI: 10.3892/ol.2018.7760

Abstract. Paclitaxel resistance is a challenge to the treatment of nasopharyngeal carcinoma (NPC). An acidic extracellular pH (pHₐ), a hallmark of solid tumors, is demonstrated to decrease the efficacy of chemotherapy. However, the precise function of acidic pHₐ in mediating chemotherapeutic resistance in NPC remains unknown. In the present study, acidic pHₐ significantly decreased the cytotoxicity of paclitaxel in NPC cells. In addition, epithelial-mesenchymal transition (EMT)-like changes were observed in NPC cells cultured at acidic pHₐ. Metadherin (MTDH), a novel oncogene, is expressed in multiple types of solid tumor, and is associated with several malignant cell characteristics, including malignant cell transformation, proliferation, angiogenesis, chemoresistance, invasion and metastasis. In the present study, MTDH expression was increased in NPC cells that had been cultured at an acidic pHₐ. Furthermore, the silencing of MTDH expression reversed EMT molecular marker expression and sensitized NPC cells to paclitaxel. Taken together, the results of the present study provide evidence to support an association between acidic pHₐ-induced paclitaxel resistance and MTDH-mediated EMT in NPC cells. Thus, targeting MTDH may provide a novel strategy for overcoming chemoresistance in NPC therapy.

Introduction

Paclitaxel is a cytotoxic agent that remains a first-line chemotherapy in the management of advanced nasopharyngeal carcinoma (NPC) (1,2). However, the development of intrinsic or acquired resistance limits the clinical efficacy of paclitaxel, which ultimately leads to tumor recurrence and a poor prognosis. Therefore, elucidation of the underlying molecular mechanisms that lead to paclitaxel resistance is an essential requirement to identify novel therapeutic strategies to overcome chemoresistance.

Extracellular pH (pHₑ) is considerably more acidic in solid tumors compared with normal tissue. Previous studies have identified that acidic pHₑ is an important characteristic of tumor tissues and is involved in cancer progression (3-7). Furthermore, acidic pHₑ has been reported to facilitate the development of resistance to chemotherapeutic drugs, including paclitaxel (8-10). Previous studies have provided evidence indicating that the ‘ion-trapping’ phenomenon mainly contributes to acidic pHₑ-mediated drug resistance (11-13). However, paclitaxel is not ionizable and therefore the drug distribution should be unaffected by pHₑ. Thus, it is important to understand the underlying molecular mechanisms responsible for the development of paclitaxel resistance.

Epithelial-mesenchymal transition (EMT) is a complex series of events, which was initially characterized as being essential during normal embryonic development (14). Previous studies have demonstrated that EMT is involved in physiological and pathological processes (15). Critically, previous studies have demonstrated an intricate association between chemoresistance and the changes associated with EMT (16). A previous study in ovarian cancer discovered that paclitaxel-resistant cells, which develop following continuous exposure to paclitaxel, exhibited the cellular and molecular characteristics of EMT (17).

Metadherin (MTDH), also known as astrocyte elevated gene-1 and lysine-rich carcinoembryonic antigen-related cell adhesion molecule-1-associated protein is an oncogene that is expressed in multiple tumors (18). Aberrant expression and dysfunction of MTDH is involved in tumor cell proliferation, survival and metastasis activity (19). Previous studies have confirmed that MTDH expression is associated with the chemoresistance of tumor cells by the regulation of a series of downstream target genes (20-24). The association between MTDH expression and EMT has been established in cervical
cancer, breast cancer and hepatocarcinoma, which may contribute to chemoresistance (25–27).

In the present study, the influence of pH on the cytotoxicity of paclitaxel in NPC cells in vitro was determined, and the associated mechanisms involved were investigated further. The results indicated that the cytotoxic efficacy of paclitaxel was markedly decreased at an acidic pH. Furthermore, it was revealed that MTDH-mediated EMT may confer acidic pH-induced paclitaxel resistance in NPC.

Materials and methods

Cell culture. The human NPC 5-8F cells were provided by the Cell Center of Central South University (Changsha, China). 5-8F cells were maintained as monolayer cultures in RPMI-1640 medium (Hyclone; GE healthcare, Chicago, IL, USA) supplemented with 10% fetal bovine serum, 100 IU/ml penicillin and 100 IU/ml streptomycin (all purchased from Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in a humidified atmosphere with 5% CO₂. Culture media with different pH values were prepared by the addition of 20 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid or 20 mM 2-(N-morpholino)ethanesulfonic acid (both purchased from Thermo Fisher Scientific, Inc.) to RPMI-1640 medium and pH values were adjusted accordingly, using NaOH or HCl to pH 7.4 or 6.8, respectively. The actual pH in the media was determined prior to and following each experiment. Cells in the exponential growth phase were used for all subsequent experiments.

Paclitaxel cytotoxicity assays. The viability of NPC 5-8F cells was analyzed using a Cell Counting Kit-8 (CCK8; Beyotime Institute of Biotechnology, Shanghai, China) to produce cell viability curves according to the manufacturer's protocol. The IC₅₀ value of paclitaxel in NPC 5-8F cells was confirmed as 2.947. IC₅₀ is defined as the concentration of paclitaxel required to produce 30% inhibition of 5-8F cells. Subsequently, NPC 5-8F cells were seeded at a density of 3x10⁴ cells/well into a 96-well plate 24 h prior to transfection. 8 µl of siRNA duplex (80 pM) was used to transfect NPC 5-8F cells transiently with MTDH siRNA (MTDH siRNA is a pool of three target-specific 19-25 nt siRNAs designed to knock down MTDH expression). Control siRNA was used to transfect NPC 5-8F cells with a pool of three non-targeting 20-25 nt siRNAs designed as a negative control. 5-8F cells (2x10⁴ cells) were seeded on a six well plate 24 h prior to transfection. 8 µl of siRNA duplex (80 pM

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. In total, 1 µg RNA was used for reverse transcription to synthesize cDNA using the High Capacity RNA-to-cDNA Kit (Applied Biosystems; Thermo Fisher Scientific Inc.). In total, 20 µl of reverse-transcription reaction components (10 µl 2X RT Buffer, 1 µl 20X RT Enzyme mix, 7 µl Nuclease-free H₂O₂ (all from Applied Biosystems; Thermo Fisher Scientific, Inc.) and 2 µl RNA) were established and incubated for 60 min at 37°C, 5 min at 95°C and then incubated at 4°C for further investigation. iQ™SYBR® Green Supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to PCR amplification in a 20 µl reaction system. The reaction system was prepared according to the following system: 10 µl iQ™SYBR® Green Supermix, 0.5 µl PCR forward primer, 0.5 µl PCR reverse primer, 8 µl Nuclease-free H₂O (Bio-Rad Laboratories, Inc.) and 1 µl cDNA template. Primer sequences used in the present study were as follows: E-cadherin forward, 5'-GCTGGACCGGAG GATTTTC-3' and reverse, 5'-CAAATCCAGGCCCG TGTTG-3'; vimentin forward, 5'-TGGTCAATCTAGTATG TGGATTTTC-3' and reverse, 5'-TGGATTTTC-3' and reverse, 5'-AGTTGCTAAATCTACTG AAGAGGA-3'; MTDH forward, 5'-GATGATGATAGTCTGG TGGTTAAA-3' and reverse, 5'-GACCTTTTTGATCATCAGG AATTG-3'; GAPDH forward, 5'-GAGTCAACGGATTGG TCGT-3' and reverse, 5'-GGTTTGTGAAGGATCTCG-3'. PCR thermocycling conditions were as follows: 3 min at 95°C followed by 40 cycles of 15 sec at 95°C and 30 sec at 60°C. The PCRs for each gene were performed in triplicate, and the mean values of fold changes were used to calculate mRNA expression. The fold change in expression of each gene was calculated using the 2ΔΔCq method (28).

Western blot analysis. The western blot assay was performed as described previously (29,30). In brief, the total protein (50 µg) was separated by 10% SDS-PAGE and the separated proteins were transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). Membranes were blocked with 5% skimmed milk at room temperature for 1 h, then incubated with the following primary antibodies at 4°C overnight: Primary antibodies used in the present study were: Mouse monoclonal antibody against E-cadherin (1:400; cat. no. sc-8426; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), mouse monoclonal antibody against vimentin (1:200; cat. no. sc-32322; Santa Cruz Biotechnology, Inc.) and rabbit polyclonal antibody against MTDH (1:800; cat. no. sc-13860-1-AP, Proteintech Group, Inc., Chicago, USA). Subsequent to washing three times in TBST, membranes were incubated with horse-radish peroxidase (HRP)-labeled goat Anti-mouse IgG (H+L; 1:4,000; cat. no. A0208) (both purchased from Beyotime Institute of Biotechnology, Shanghai, China) and 1 µl 10,000 dilution of DAB substrate solution (Bio-Rad Laboratories, Inc.) and incubated for 5 min at room temperature. The films were visualized using the BeyoECL Plus Detection System (Beyotime Institute of Biotechnology) and the images were obtained by X-ray film exposure. For normalization of protein loading, mouse monoclonal antibody against β-actin (1:1,000; cat. no. AF0003; Beyotime Institute of Biotechnology) was used. All antibodies were diluted using primary antibody dilution buffer or secondary antibody dilution buffer (both purchased from Beyotime Institute of Biotechnology). Each experiment was performed in triplicate.
siRNA) or control siRNA was diluted into 100 μl siRNA transfection medium (cat. no. sc-36868; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) as solution A. Furthermore, 6 μl of siRNA transfection reagent (cat. no. sc-29528; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was diluted into 100 μl siRNA transfection medium as solution B. Solution A and B were mixed and incubated for 45 min at room temperature. In total, 0.8 ml siRNA transfection medium was added to each tube containing the siRNA transfection reagent mixture (solution A and B), and overlayed onto the washed cells. Cells were incubated for 5-7 h at 37°C in a 5% CO₂ incubator. To determine the efficiency of the siRNA knockdown, the transfected cells were collected 3 days after transfection and the protein levels of MTDH were assessed using western blotting, as aforementioned.

**Statistical analysis.** All statistical analyses were conducted using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Quantitative data are expressed as the mean ± standard deviation. Statistical differences between groups were compared using two-tailed unpaired Student's t-tests. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Acidic pH decreases the cytotoxicity of paclitaxel in NPC cells.** To confirm the association between acidic pH, and the sensitivity of NPC to paclitaxel, the IC₅₀ value for paclitaxel in NPC 5-8F cells was confirmed as 2.947 (Fig. 1A). The viability of NPC 5-8F cells, incubated in normal (pH 7.4) or acidic (pH 6.8) medium, following paclitaxel stimulation at its IC₅₀ for 48 h, was evaluated using CCK-8 assays. As presented in Fig. 1B, the survival rate of NPC 5-8F cells was 30.32±3.34 compared with 45.58±6.34 (P<0.05), incubated in normal (pH 7.4) or acidic (pH 6.8) medium, respectively. These results indicated that acidic medium enhanced the survival rate of NPC 5-8F cells and that acidic pH significantly decreased the cytotoxicity of paclitaxel in NPC cells.

**EMT-like features of NPC cells grown in acidified medium.** In order to investigate whether EMT is involved in acidic pHₕ-induced paclitaxel resistance, the key markers of EMT were measured in NPC 5-8F cells grown in acidified medium for 48 h. Phase-contrast microscopy revealed that NPC 5-8F cells cultured in acidic medium underwent several morphological changes, with some loss of adherence and cell-to-cell contact and the induction of a spindle-like form (Fig. 2A). The results of qPCR and western blot analysis demonstrated that expression of the characteristic mesenchymal markers vimentin and N-cadherin were upregulated in NPC 5-8F cells cultured at pHₕ 6.8, compared with that of pHₕ 7.4 (Fig. 2B and C). In addition, a significant decrease in the expression of the epithelial maker E-cadherin was observed when NPC 5-8F cells were cultured in acidic medium (Fig. 2B and C). These results indicated that the acidic pHₕ-induced paclitaxel-resistant NPC cells acquired the EMT phenotype.

**Acidic pHₕ enhances the expression of MTDH in NPC cells.** In the present study, the potential molecular mechanism responsible for the EMT-like phenotypic changes in acidic pHₕ-induced paclitaxel resistance in NPC cells was explored. In a previous study, it was demonstrated that MTDH was increased and promoted EMT in squamous cell carcinoma of the head and neck (SCCHN) (30). Another previous report revealed that increased MTDH expression is also associated with drug resistance, including that of paclitaxel, in breast cancer, hepatocellular carcinoma and prostate cancer (23,31). Therefore, the differences in MTDH expression in NPC cells cultured at a pHₕ of 6.8 compared with that at a pHₕ of 7.4 were investigated further. As presented in Fig. 3A, MTDH mRNA levels were increased when cultured in acidic medium. In addition, western blot analysis demonstrated that MTDH protein expression was significantly increased in response to an acidic culture environment (Fig. 3B). The results from the present study indicated that MTDH may be associated with an acidic pHₕ-mediated EMT and paclitaxel resistance in NPC cells.

**Silencing of MTDH reversed the EMT phenotype and sensitized NPC cells to paclitaxel in an acidic pHₕ environment.** To determine whether increased MTDH expression was associated with EMT in NPC cells, siRNA was used to downregulate MTDH expression in NPC cells cultured at a pHₕ of 6.8. Cells transfected with MTDH siRNA demonstrated decreased MTDH expression, accompanied by decreased vimentin expression and increased E-cadherin expression, compared with NPC 5-8F cells transfected with the control vector (Fig. 4A). The results demonstrated that E-cadherin downregulation and vimentin upregulation, induced by acidic pHₕ were attenuated by MTDH RNA interference in NPC 5-8F
cells. This is indicative of a crucial function for MTDH in the induction of the EMT phenotype in NPC cells, stimulated by an acidic pH environment. Finally, the effects of inhibiting MTDH on the cytotoxicity of paclitaxel in NPC cells in acidic pH environment were investigated. As presented in Fig. 4B, the cell survival rate of NPC 5-8F cells at an acidic pH in the presence of paclitaxel at its IC_{50} was 45.92±6.3, compared with 35.72±2.27 in the MTDH-downregulated 5-8F cells (P<0.05). These results revealed that MTDH knockdown significantly restored the sensitivity of NPC 5-8F cells to paclitaxel, previously decreased in response to an acidic pH environment.

Discussion

NPC is one of the most common malignant tumors in southern China and Southeast Asia, with ~70% of newly diagnosed NPC cases, and thus is classified as locoregionally advanced disease (32). Paclitaxel is now routinely used to treat advanced NPC. However, the development of paclitaxel resistance is a significant barrier to the treatment of NPC. Therefore, elucidation of the molecular mechanisms underlying paclitaxel resistance is crucial to enhance the efficacy of treatment and to improve the survival rates of patients with NPC.

Acidic pH, a hallmark of solid tumors, is thought to decrease the efficacy of chemotherapeutic regimens (33-35). However, the exact function of acidic pH in mediating chemotherapeutic resistance in NPC remains unclear. In the present study, it was demonstrated that acidic pH decreased the cytotoxicity of paclitaxel in NPC 5-8F cells in vitro. The results from the present study are consistent with those of a previous study that identified that acidic pH leads to decreased paclitaxel sensitivity in murine EMT6 cells and the human bladder...
carcinoma cell line MGH-U1 (36). However, other previous \textit{in vitro} studies have revealed no significant differences in the paclitaxel toxicity of MCF-7 cells cultured at a pH$_{4}$ of 6.8 compared with 7.4 (12,13). The discrepancies in the results between distinct cancer cell lines indicated that the effects of acidic pH$_{4}$ on paclitaxel resistance may be cell line-specific.

Low pH$_{4}$ forms a physiological drug barrier, namely ion trapping, which has a negative effect on the efficacy of weakly basic chemotherapeutics, yet is more suited to weaker acidic therapeutics (9,12). Previous studies have demonstrated that ion trapping mainly contributes to acidic pH$_{4}$-mediated chemoresistance. Owing to the complex structure of paclitaxel, which is composed of acidic and basic domains, the drug is not ionizable under physiological conditions, and thus its efficacy should be unaffected by ion trapping (12,37). EMT is considered to be an essential feature of epithelial malignant tumor cells and is accompanied by increased vimentin and N-cadherin expression, and decreased E-cadherin expression (38-40). Previous studies have revealed that acidic pH$_{4}$ induces EMT-like changes in human melanoma cells and Lewis lung carcinoma, which further promotes tumor progression (41,42). In the present study, the transformation of fibroblast-like morphology, epithelial marker E-cadherin downregulation, and upregulation of mesenchymal markers vimentin and N-cadherin, were observed in NPC 5-8F cells cultured at a pH$_{4}$ of 6.8, suggesting that acidic pH$_{4}$ may induce EMT-like changes in NPC cells.

EMT is thought to be involved in wound healing, stem cell behavior, development and the progression of cancer. Emerging evidence has revealed a strong link between resistance to chemotherapy and the induction of EMT in cancer (43). A number of studies have indicated that chemoresistant cancer cells undergo morphological and molecular changes similar to EMT. In colorectal cancer, oxaliplatin-resistant cells acquired the ability to migrate and invade with phenotypic changes resembling those of EMT (44). In pancreatic and ovarian cancer, stable cell lines resistant to gemcitabine and paclitaxel established by continuous exposure were able to undergo EMT with increased Snail and Twist expression (17,45). A previous study also revealed that EMT is necessary for acquired resistance to cisplatin and increases the metastatic potential of NPC cells (46). In addition, another \textit{in vitro} and \textit{in vivo} study demonstrated that paclitaxel-resistant NPC cells exhibited characteristic EMT phenotypes, and forkhead box C2 promoted chemoresistance in NPC via the induction of EMT (47). Taken together, this evidence, together with the results of the present study supports the conclusion that EMT is responsible for acidic pH$_{4}$-induced paclitaxel resistance in NPC cells.

Previous results indicated that acidic pH$_{4}$ was able to promote tumor progression through the increase in the expression of specific genes, including those encoding vascular endothelial growth factor, interleukin-8 and matrix metalloproteinase-9 (48-51). MTDH, a novel oncogene, is prevalently expressed in numerous solid tumors, including SCCHN, and is involved in multiple cellular behaviors associated with malignant cells, including malignant cell transformation, proliferation, angiogenesis, invasion and metastasis (30,52-55). There is further evidence to indicate that MTDH modulates the sensitivity of cancer cells to chemotherapeutic agents (20,56). In the present study, the results demonstrated that MTDH expression was significantly enhanced in NPC cells cultured in an acidic medium. In a previous study, our group identified that MTDH promoted EMT in SCCHN (30). In the present study, the potential function of MTDH in acidic pH$_{4}$-mediated EMT was investigated further. The data demonstrated that knock-down of MTDH abrogated the acidic pH$_{4}$-induced suppression of E-cadherin and increased vimentin expression in NPC 5-8F cells; which indicated that MTDH is involved in acidic pH$_{4}$-mediated EMT-like changes in NPC cells. Furthermore, the cytotoxicity of paclitaxel in NPC cells recovered, whereas MTDH was knocked down, under acidic conditions. Taken together, these results support the existence of an association between acidic pH$_{4}$-induced paclitaxel resistance and MTDH upregulation-mediated EMT in NPC cells.

In conclusion, the results of the present study indicated that MTDH-mediated EMT may be an alternative mechanism through which acidic pH$_{4}$ promotes paclitaxel resistance in NPC. Thus, normalization of pH$_{4}$ may be a reasonable strategy for tumor therapy. Furthermore, targeting MTDH may provide a novel strategy for overcoming chemoresistance in NPC therapy. However, further \textit{in vivo} experiments are required to confirm whether MTDH is a viable target for therapy.

Acknowledgements

The present study was funded by the National Natural Science Foundation of China (grant no. 81402232).

References

1. Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, Foo KF, Lim WT, Tan T and Tan EH: Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: A Phase II trial using a triplet combination. Cancer 103: 569-575, 2005.
2. Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW, Tay MH, Poon D and Tan EH: Triple combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer 113: 1332-1337, 2008.
3. Vaupel P, Kalliomäki F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49: 6449-6465, 1989.
4. Gatenby RA and Gillies RJ: A microenvironmental model of carcinogenesis. Nat Rev Cancer 8: 56-61, 2008.
5. Fang JS, Gillies RD and Gatenby RA: Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18: 330-337, 2008.
6. Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV and Gillies RJ: Imaging pH and metastasis. NMR Biomed 24: 582-591, 2011.
7. Peppicelli S, Bianchini F and Calorini L: Extracellular acidity, a ‘reappreciated’ trait of tumor environment driving malignancy: Perspectives in diagnosis and therapy. Cancer Metastasis Rev 33: 823-832, 2014.
8. Raghunand N and Gillies RJ: pH and drug resistance in tumors. Drug Resist Updat 3: 39-47, 2000.
9. Wojtkowiak JW, Verduzco D, Schramm KJ and Gillies RJ: Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 8: 2032-2038, 2011.
10. Trédan O, Park S, Chiche J and Pouysségur J: Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 13: 611-623, 2013.
11. Mahoney BP, Raghunand N, Baggerly K and Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66: 1207-1218, 2003.
13. Raghunand N, Mahoney BP and Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmaco kinetic and toxicologic behavior of basic chemotherapeutic agents. Biochem Pharmacol 66: 1219-1229, 2003.

14. Thiery JP: Epithelial-mesenchymal transitions in development and pathology. Curr Opin Cell Biol 15: 740-746, 2003.

15. Thiery JP, Acloque H, Yang RU and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.

16. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S and Sarkar FH: Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118, 2010.

17. Cancedda R, Brabak M, Tetzlaff M, Ito N, Nawa A and Kikkawa F: Chemo-resistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283, 2007.

18. Lee SG, Kang DC, De Salle R, Sarkar D and Fisher PB: AEG-1/MTDH/LYRIC: the beginning: Initial cloning, structure, expression profile, and regulation of expression. Adv Cancer Res 120: 1-38, 2013.

19. Emdad L, Das SK, Dass Gupta, S Hu B, Sarkar D and Fisher PB: AEG-1/MTDH/LYRIC: Signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. Adv Cancer Res 120: 211-270, 2014.

20. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG and Kang Y: MTDH activation by 8q22 genomic gain promotes chemo-resistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15: 9-20, 2009.

21. You KK, Li Z, Reschitzka N, Su ZZ, Chen D, Forcier T, Thak S, Saxena U, Hansen U, Fisher PB and Sarkar D: Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci USA 106: 12938-12943, 2009.

22. You KK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB and Sarkar D: Molecular mechanism of chemo-resistance by astrocyte elevated gene-1. Cancer Res 70: 3249-3258, 2010.

23. Meng X, Thiel KW and Leslie KK: Drug resistance mediated by AEG-1/MTDH/LYRIC. Adv Cancer Res 120: 135-157, 2013.

24. Zhang J, Zhang Y, Liu S, Zhang Q, Wang Y, Tong L, Chen X, Ji Y, Shang Q, Xu B, et al: Metadherin confers chemo-resistance of cervical cancer cells by inducing autophagy and activating ERK/NF-κB pathway. Tumour Biol 34: 2433-2440, 2013.

25. Liu X, Wang D, Liu H, Feng Y, Zhu T, Zhang L, Zhu B and Zhang Y: Knockdown of astrocyte elevated gene-1 (AEG-1) in cervical cancer cells decreases their invasiveness, epithelial to mesenchymal transition, and chemoresistance. Cell Cycle 13: 1702-1707, 2014.

26. Ward A, Balwierz A, Zhang JD, Kübler M, Pawiyan T, Hielscher W, Ward A, Balwierz A, Zhang JD, Kükbell M, Küblbeck M, De Salle R, Sarkar D and Fisher PB: AEG-1/MTDH/LYRIC: Signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. Adv Cancer Res 120: 211-270, 2014.

27. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by comparative CT (threshold cycle) method. Nat Protoc 3: 1101-1108, 2008.

28. Yu C, Liu Y, Huang D, Dai Y, Cai G, Sun J, Xu T, Tian Y and Zhang X: TGFB-B1 mediates epithelial to mesenchymal transition via the TGF-B1/Smad pathway in squamous cell carcinoma of the head and neck. Cancer Res 65: 1581-1587, 2005.

29. Yu C, Liu Y, Tan H, Li G, Su Z, Ren S, Zhu G, Tian Y, Qiu Y and Zhang X: Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signaling pathway-mediated epithelial-mesenchymal transition. Cancer Lett 343: 108-114, 2014.

30. Zhang C, Li HZ, Qian BJ, Liu CM, Guo F and Lin MC: MTDH/AEG-1-based DNA vaccine suppresses metastasis and enhances chemosensitivity to paclitaxel in pelvic lymph node metastasis. Biomed Pharmacother 70: 217-226, 2015.

31. Chua ML, Wey ET, Hsiai CH and Chan ATC: Nasopharyngeal carcinoma. Lancet 387: 1012-1024, 2016.

32. Rotin D, Robinson B and Tannock IF: Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: Potential implications for cell death in tumors. Cancer Metastasis Rev 13: 381-394, 1994.

33. Tannock IF and Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49: 4373-4384, 1989.